Truist Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $30
Author: Benzinga Newsdesk | July 21, 2025 06:54am
Truist Securities analyst Danielle Brill initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $30.